Company Overview
American HealthCare Capital is pleased to exclusively present a groundbreaking SaMD (Software as a Medical Device) company focused on non-invasively measuring and identifying imbalances in the Autonomic Nervous System. The company’s diagnostic technology is patented and FDA 510K-cleared and is used by a myriad of physicians, medical providers, and researchers globally to detect imbalances that can be used for early detection and preventive care of a host of chronic medical issues.
Over 90 million people suffer every day from multiple symptoms that doctors frequently cannot diagnose or misdiagnose. These patients often have some sort of autonomic dysfunction which traditional end organ diagnostic methods can’t and don’t evaluate. As a result, patients receive expensive medications to treat their symptoms, but are not cured because the underlying cause isn’t properly identified. It’s a frustrating and unhealthy experience for the patient and disappointing for the doctors. This company’s technology gets to the root of chronic issues such as hypertension and diabetes, as well as concussion detection, seizure prediction, PTSD and addiction treatment, and more.
The Opportunity
The company is seeking a strategic partner or investor who recognizes the groundbreaking nature of this technology as they scale, build/gain staffing infrastructure, develop sales & marketing, and invest in next generation product development. As a result, the company is open to a variety of deal structures.
